Anlotinib Plus Anti-PD-1 Antibody AK105 for Advanced Pancreatic Cancer

• Status: Not yet recruiting
• Trial end date: 2024-02-29
• Target enrollment: 0
• Participant gender: All

Summary

This study was designed to explore the clinical efficacy of Anlotinib combined with Anti-PD-1 antibody AK105 in the treatment of third- and above -line advanced pancreatic cancer patients, in order to find a better therapy strategy for pancreatic cancer patients.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Peking Union Medical College Hospital

Criteria

Inclusion Criteria:

• locally advanced or metastatic pancreatic cancer (PC),

• histologically or cytologically proven diagnosis of adenocarcinoma or adenosquamous carcinoma,

• failed to second-line chemotherapy for PC,

• 18-75 years of age,

• an Eastern Cooperative Oncology Group performance status score of 0 to 1,

• adequate organ functions

Exclusion Criteria:

• had received PD 1 /CTLA 4 antibody treatment

• had received anti-VEGFR inhibitors or antibodies